Publication:
Aromatase inhibitory activity of 1,4-naphthoquinone derivatives and QSAR study

dc.contributor.authorPrachayasittikul V.
dc.contributor.authorPingaew R.
dc.contributor.authorWorachartcheewan A.
dc.contributor.authorSitthimonchai S.
dc.contributor.authorNantasenamat C.
dc.contributor.authorPrachayasittikul S.
dc.contributor.authorRuchirawat S.
dc.contributor.authorPrachayasittikul V.
dc.date.accessioned2021-04-05T03:22:17Z
dc.date.available2021-04-05T03:22:17Z
dc.date.issued2017
dc.date.issuedBE2560
dc.description.abstractA series of 2-amino(chloro)-3-chloro-1,4-naphthoquinone derivatives (1-11) were investigated for their aromatase inhibitory activities. 1,4-Naphthoquinones 1 and 4 were found to be the most potent compounds affording IC50 values 5.2 times lower than the reference drug, ketoconazole. A quantitative structure-activity relationship (QSAR) model provided good predictive performance (R2 CV = 0.9783 and RMSECV = 0.0748) and indicated mass (Mor04m and H8m), electronegativity (Mor08e), van der Waals volume (G1v) and structural information content index (SIC2) descriptors as key descriptors governing the activity. To investigate the effects of structural modifications on aromatase inhibitory activity, the model was employed to predict the activities of an additional set of 39 structurally modified compounds constructed in silico. The prediction suggested that the 2,3-disubstitution of 1,4-naphthoquinone ring with halogen atoms (i.e., Br, I and F) is the most effective modification for potent activity (1a, 1b and 1c). Importantly, compound 1b was predicted to be more potent than its parent compound 1 (11.90-fold) and the reference drug, letrozole (1.03-fold). The study suggests the 1,4-naphthoquinone derivatives as promising compounds to be further developed as a novel class of aromatase inhibitors. © 2017, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved.
dc.format.mimetypeapplication/pdf
dc.identifier.citationEXCLI Journal. Vol 16, (2017), p.714-726
dc.identifier.doi10.17179/excli2017-309
dc.identifier.issn16112156
dc.identifier.other2-s2.0-85019633218
dc.identifier.urihttps://hdl.handle.net/20.500.14740/4161
dc.rights.holderScopus
dc.subject.other1,4 naphthoquinone derivative
dc.subject.other2 amino(chloro) 3 chloro 1,4 naphthoquinone derivative
dc.subject.otherCompound 1
dc.subject.otherCompound 10
dc.subject.otherCompound 11
dc.subject.otherCompound 2
dc.subject.otherCompound 3
dc.subject.otherCompound 4
dc.subject.otherCompound 5
dc.subject.otherCompound 6
dc.subject.otherCompound 7
dc.subject.otherCompound 8
dc.subject.otherCompound 9
dc.subject.otherDoxorubicin
dc.subject.otherKetoconazole
dc.subject.otherLetrozole
dc.subject.otherUnclassified drug
dc.subject.otherArticle
dc.subject.otherComputer model
dc.subject.otherControlled study
dc.subject.otherCytotoxicity
dc.subject.otherDrug determination
dc.subject.otherDrug structure
dc.subject.otherDrug synthesis
dc.subject.otherHuman
dc.subject.otherHuman cell
dc.subject.otherIC50
dc.subject.otherQuantitative structure activity relation
dc.titleAromatase inhibitory activity of 1,4-naphthoquinone derivatives and QSAR study
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85019633218&doi=10.17179%2fexcli2017-309&partnerID=40&md5=6eeb41e54bf47070f70cf31e8a3adb75

Files